摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-([6-(1-ethylpropoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy)benzoic acid | 1072002-45-9

中文名称
——
中文别名
——
英文名称
3-([6-(1-ethylpropoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy)benzoic acid
英文别名
3-[(1-Methyl-6-pentan-3-yloxybenzimidazol-2-yl)methoxy]benzoic acid
3-([6-(1-ethylpropoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy)benzoic acid化学式
CAS
1072002-45-9
化学式
C21H24N2O4
mdl
——
分子量
368.433
InChiKey
AFTJKIAEKXQPNY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    27
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    73.6
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • FUSED BICYCLIC HETEROARYL DERIVATIVE
    申请人:SHIMADA Kousei
    公开号:US20100048564A1
    公开(公告)日:2010-02-25
    The present invention relates to a novel fused bicyclic heteroaryl derivative or a pharmacologically acceptable salt thereof, which has an excellent hypoglycemic effect or treats and/or prevents the onset of a disorder of carbohydrate or lipid metabolism or a disease mediated by peroxisome proliferator-activated receptor (PPAR) γ. A compound having the general formula (I): wherein R 1 represents a C 1 -C 6 alkyl group, a C 6 -C 10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; R 2 represents a C 1 -C 6 alkyl group; R 3 represents a C 6 -C 10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; Q represents a group represented by the formula ═CH— or a nitrogen atom; and Substituent Group a represents a halogen atom, a C 1 -C 6 alkyl group, a C 1 -C 6 hydroxyalkyl group, and the like, or a pharmacologically acceptable salt thereof.
    本发明涉及一种新型融合的双环杂环取代基衍生物或其药学上可接受的盐,该化合物具有出色的降血糖作用,或用于治疗和/或预防碳水化合物或脂质代谢紊乱或由过氧化物酶体增殖物激活受体(PPAR)γ介导的疾病。该化合物具有通式(I):其中R1表示C1-C6烷基,C6-C10芳基,可能被1至5个独立选择的取代基a取代,或类似的基团;R2表示C1-C6烷基;R3表示C6-C10芳基,可能被1至5个独立选择的取代基a取代,或类似的基团;Q表示由═CH-或氮原子表示的基团;取代基a表示卤原子,C1-C6烷基,C1-C6羟基烷基等,或其药学上可接受的盐。
  • FUSED BICYCLIC HETEROARYL DERIVATIVES
    申请人:Daiichi Sankyo Company, Limited
    公开号:EP2138484A1
    公开(公告)日:2009-12-30
    Problem to be Solved The present invention relates to a novel fused bicyclic heteroaryl derivative or a pharmacologically acceptable salt thereof, which has an excellent hypoglycemic effect or treats and/or prevents the onset of a disorder of carbohydrate or lipid metabolism or a disease mediated by peroxisome proliferator-activated receptor (PPAR) γ. Solution A compound having the general formula (I): wherein R1 represents a C1-C6 alkyl group, a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; R2 represents a C1-C6 alkyl group; R3 represents a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; Q represents a group represented by the formula =CH- or a nitrogen atom; and Substituent Group a represents a halogen atom, a C1-C6 alkyl group, a C1-C6 hydroxyalkyl group, and the like, or a pharmacologically acceptable salt thereof.
    有待解决的问题 本发明涉及一种新型融合双环杂芳基衍生物或其药理学上可接受的盐,该衍生物具有极佳的降血糖效果,或可治疗和/或预防碳水化合物或脂质代谢紊乱或由过氧化物酶体增殖激活受体(PPAR)γ介导的疾病的发生。 解决方案 具有通式(I)的化合物: 其中 R1 代表 C1-C6 烷基、可被 1 至 5 个独立选自取代基 a 的基团取代的 C6-C10 芳基或类似基团; R2 代表 C1-C6 烷基; R3 代表可被 1 至 5 个独立选自取代基 a 的基团取代的 C6-C10 芳基或类似基团;Q 代表由式 =CH- 代表的基团或氮原子;取代基 a 代表卤素原子、C1-C6 烷基、C1-C6 羟烷基等,或其药理上可接受的盐。
查看更多